By assigning weight to health outcomes and calculating the benefits from raloxifene compared with placebo and from tamoxifen compared with placebo, researchers developed a benefit/risk index for the use of these agents as chemo preventives in postmenopausal women at high risk for breast cancer. As seen in the indices in the article, the researchers found raloxifene better than tamoxifen for women with a uterus; for women without a uterus, the profiles were similar. The complete findings and indices can be viewed in the May 2 edition of Journal of Clinical Oncology: http://jco.ascopubs.org/content/early/2011/04/26/JCO.2010.33.0258.long.
